Molecular biomarkers of residual disease after surgical debulking of high-grade serous ovarian cancer
about
Does a standardized preoperative algorithm of clinical data improve outcomes in patients with ovarian cancer? A quality improvement projectA framework for a personalized surgical approach to ovarian cancer.Suboptimal cytoreduction in ovarian carcinoma is associated with molecular pathways characteristic of increased stromal activationElevated expression of FABP3 and FABP4 cooperatively correlates with poor prognosis in non-small cell lung cancer (NSCLC).ADH1B: From alcoholism, natural selection, and cancer to the human phenome.Pooled Clustering of High-Grade Serous Ovarian Cancer Gene Expression Leads to Novel Consensus Subtypes Associated with Survival and Surgical Outcomes.A multicenter assessment of the ability of preoperative computed tomography scan and CA-125 to predict gross residual disease at primary debulking for advanced epithelial ovarian cancer.IPI59: An Actionable Biomarker to Improve Treatment Response in Serous Ovarian Carcinoma PatientsSparse generalized linear model with L0 approximation for feature selection and prediction with big omics data.Revisiting ovarian cancer microenvironment: a friend or a foe?Neoadjuvant chemotherapy for advanced epithelial ovarian cancer. Who really benefits?Identification of differentially expressed genes and signaling pathways in ovarian cancer by integrated bioinformatics analysis.Exogenous FABP4 increases breast cancer cell proliferation and activates the expression of fatty acid transport proteins.ADH1B promotes mesothelial clearance and ovarian cancer infiltration.FABP4 as a key determinant of metastatic potential of ovarian cancer
P2860
Q30945812-55BD17D6-D4DF-42B2-9254-3F7DA7CAB8E9Q35926352-15CFB7DA-E67E-4FDF-BD5A-F316A0BC5379Q36372792-C7A386A5-6AE9-48D5-88CF-51DF744C8A17Q37564704-B4BA7364-C237-48A5-B791-32AD5DC958FCQ38738691-2202680B-6809-41EA-8CE2-4C529E9C5092Q38747875-73E8798D-F49F-4A29-9C08-129E8C44DE50Q40331453-DFDB9152-6235-4864-A475-C381D45F2CA2Q41687350-6FD0845E-FEE3-41F7-8F1A-A50F91C14FBDQ47110118-B6962375-5F1A-45D1-8790-8C8A685D3677Q47773956-8618355E-0667-4E2B-8696-57E02841FC1CQ50054786-A652328F-29BA-4E15-BF8A-829AE5765051Q54118989-1BB78209-99CE-4834-AA5E-B0077880045CQ55025650-FB8BDE72-7916-4C6E-9A90-67B407850EDDQ55267167-E59404FB-8280-4A9A-8E48-C5FD4F8F0D50Q59123157-E8677E79-7844-4F6F-B693-0B6ADBF6F0FC
P2860
Molecular biomarkers of residual disease after surgical debulking of high-grade serous ovarian cancer
description
2014 nî lūn-bûn
@nan
2014 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Molecular biomarkers of residu ...... gh-grade serous ovarian cancer
@ast
Molecular biomarkers of residu ...... gh-grade serous ovarian cancer
@en
type
label
Molecular biomarkers of residu ...... gh-grade serous ovarian cancer
@ast
Molecular biomarkers of residu ...... gh-grade serous ovarian cancer
@en
prefLabel
Molecular biomarkers of residu ...... gh-grade serous ovarian cancer
@ast
Molecular biomarkers of residu ...... gh-grade serous ovarian cancer
@en
P2093
P2860
P50
P1476
Molecular biomarkers of residu ...... gh-grade serous ovarian cancer
@en
P2093
Alpa M Nick
Anil K Sood
Bulent Ozpolat
Erin K Crane
Gabriel Lopez-Berestein
Heather J Dalton
Jamie Guenthoer
Keith A Baggerly
Robert L Coleman
Sherry Y Wu
P2860
P304
P356
10.1158/1078-0432.CCR-14-0445
P407
P577
2014-04-22T00:00:00Z